An important challenge in the management of patients with type 2 diabetes is cardiovascular
disease (CVD) prevention. While it is well established that intensive glycemic control …

Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing
cardiovascular disease (CVD)—namely myocardial infarction, heart failure, and stroke …

Hyperglycemia is the major risk factor for microvascular complications in patients with type 2
diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and …

Diabetes mellitus type 2 (T2DM) has been associated with an increased cardiovascular risk.
Improving glycaemia or other traditional cardiovascular risk factors may reduce …

The US Food and Drug Administration (FDA) issued a diabetes guidance in 2008 mandating
that all new antidiabetes drugs rule out excess cardiovascular (CV) risk, defined as an upper …

Objective To review recent glycemia trials focused on reducing cardiovascular disease
(CVD) risk in patients with type 2 diabetes and to describe how the results of these studies …

It is well known that the multiple factors contributing to the pathogenesis of type 2 diabetes
(T2D) confer an increased risk of developing cardiovascular disease (CVD). Although the …

Lack of conclusive beneficial effects of strict glycemic control on macrovascular
complications has been very frustrating for clinicians involved in care of patients with …

Background Cardiovascular disease remains the primary source of morbidity and mortality
in type 2 diabetes (T2D). We characterized the change over time in the use of evidence …

This review examines recent randomized controlled cardiovascular (CV) outcome trials of
glucose‐lowering therapies in type 2 diabetes and their impact on the treatment of patients …